H H Yoon1, N R Foster2, J P Meyers2, P D Steen3, D W Visscher4, R Pillai5, D M Prow6, C M Reynolds7, B T Marchello8, R B Mowat9, B I Mattar10, C Erlichman1, M P Goetz11. 1. Division of Medical Oncology. 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester. 3. Department of Medical Oncology, Meritcare Hospital CCOP, Fargo. 4. Department of Anatomic Pathology, Mayo Clinic, Rochester. 5. Pathwork Diagnostics, Redwood City. 6. Department of Medical Oncology, Iowa Oncology Research Association CCOP, Des Moines. 7. Department of Hematology/Medical Oncology, Michigan Cancer Research Consortium, Ann Arbor. 8. Department of Medical Oncology, Montana Cancer Consortium, Billings. 9. Department of Medical Oncology/Hematology, Toledo Community Hospital Oncology Program CCOP, Toledo. 10. Department of Medical Oncology/Hematology, Wichita Community Clinical Oncology Program, Wichita, USA. 11. Division of Medical Oncology goetz.matthew@mayo.edu.
Abstract
BACKGROUND: Carboplatin (C) and paclitaxel (P) are standard treatments for carcinoma of unknown primary (CUP). Everolimus, an mTOR inhibitor, exhibits activity in diverse cancer types. We did a phase II trial combining everolimus with CP for CUP. We also evaluated whether a gene expression profiling (GEP) test that predicts tissue of origin (TOO) could identify responsive patients. PATIENTS AND METHODS: A tumor biopsy was required for central confirmation of CUP and GEP. Patients with metastatic, untreated CUP received everolimus (30 mg weekly) with P (200 mg/m(2)) and C (area under the curve 6) every 3 weeks. The primary end point was response rate (RR), with 22% needed for success. The GEP test categorized patients into two groups: those having a TOO where CP is versus is not considered standard therapy. RESULTS: Of 45 assessable patients, the RR was 36% (95% confidence interval 22% to 51%), which met criteria for success. Grade ≥3 toxicities were predominantly hematologic (80%). Adequate tissue for GEP was available in 38 patients and predicted 10 different TOOs. Patients with a TOO where platinum/taxane is a standard (n = 19) tended to have higher RR (53% versus 26%) and significantly longer PFS (6.4 versus 3.5 months) and OS (17.8 versus 8.3 months, P = 0.005), compared with patients (n = 19) with a TOO where platinum/taxane is not standard. CONCLUSIONS: Everolimus combined with CP demonstrated promising antitumor activity and an acceptable side-effect profile. A tumor biomarker identifying TOO may be useful to select CUP patients for specific antitumor regimens. CLINICALTRIALSGOV: NCT00936702.
BACKGROUND: Carboplatin (C) and paclitaxel (P) are standard treatments for carcinoma of unknown primary (CUP). Everolimus, an mTOR inhibitor, exhibits activity in diverse cancer types. We did a phase II trial combining everolimus with CP for CUP. We also evaluated whether a gene expression profiling (GEP) test that predicts tissue of origin (TOO) could identify responsive patients. PATIENTS AND METHODS: A tumor biopsy was required for central confirmation of CUP and GEP. Patients with metastatic, untreated CUP received everolimus (30 mg weekly) with P (200 mg/m(2)) and C (area under the curve 6) every 3 weeks. The primary end point was response rate (RR), with 22% needed for success. The GEP test categorized patients into two groups: those having a TOO where CP is versus is not considered standard therapy. RESULTS: Of 45 assessable patients, the RR was 36% (95% confidence interval 22% to 51%), which met criteria for success. Grade ≥3 toxicities were predominantly hematologic (80%). Adequate tissue for GEP was available in 38 patients and predicted 10 different TOOs. Patients with a TOO where platinum/taxane is a standard (n = 19) tended to have higher RR (53% versus 26%) and significantly longer PFS (6.4 versus 3.5 months) and OS (17.8 versus 8.3 months, P = 0.005), compared with patients (n = 19) with a TOO where platinum/taxane is not standard. CONCLUSIONS: Everolimus combined with CP demonstrated promising antitumor activity and an acceptable side-effect profile. A tumor biomarker identifying TOO may be useful to select CUP patients for specific antitumor regimens. CLINICALTRIALSGOV: NCT00936702.
Authors: Sarah E Kerr; Catherine A Schnabel; Peggy S Sullivan; Yi Zhang; Veena Singh; Brittany Carey; Mark G Erlander; W Edward Highsmith; Sarah M Dry; Elena F Brachtel Journal: Clin Cancer Res Date: 2012-05-30 Impact factor: 12.531
Authors: John D Hainsworth; Catherine A Schnabel; Mark G Erlander; David W Haines; F Anthony Greco Journal: Clin Colorectal Cancer Date: 2011-10-14 Impact factor: 4.481
Authors: M Gross-Goupil; A Fourcade; E Blot; N Penel; S Négrier; S Culine; L Chaigneau; T Lesimple; F Priou; A Lortholary; M C Kaminsky; J Provencal; E Voog; J Bouzy; A Laplanche; K Fizazi Journal: Eur J Cancer Date: 2012-02-06 Impact factor: 9.162
Authors: Jeffrey S Ross; Kai Wang; Laurie Gay; Geoff A Otto; Emily White; Kiel Iwanik; Gary Palmer; Roman Yelensky; Doron M Lipson; Juliann Chmielecki; Rachel L Erlich; Andrew N Rankin; Siraj M Ali; Julia A Elvin; Deborah Morosini; Vincent A Miller; Philip J Stephens Journal: JAMA Oncol Date: 2015-04 Impact factor: 31.777
Authors: G R Varadhachary; S Karanth; W Qiao; H R Carlson; M N Raber; J D Hainsworth; F A Greco Journal: Int J Clin Oncol Date: 2013-06-28 Impact factor: 3.402
Authors: Shernan G Holtan; Preston D Steen; Nathan R Foster; Charles Erlichman; Fabiola Medeiros; Matthew M Ames; Stephanie L Safgren; David L Graham; Robert J Behrens; Matthew P Goetz Journal: PLoS One Date: 2012-07-17 Impact factor: 3.240
Authors: Alaa T Alshareeda; Batla S Al-Sowayan; Reem R Alkharji; Sahar M Aldosari; Abdullah M Al Subayyil; Ayidah Alghuwainem Journal: J Cancer Date: 2020-04-06 Impact factor: 4.207
Authors: Stefan Kolling; Ferdinando Ventre; Elena Geuna; Melissa Milan; Alberto Pisacane; Carla Boccaccio; Anna Sapino; Filippo Montemurro Journal: Front Oncol Date: 2020-01-17 Impact factor: 6.244